Contact:Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344Burns McClellan, Inc.Lisa Burns Justin Jackson (Media)Email: firstname.lastname@example.orgPhone: 212-213-0006
Intra-Cellular Therapies' (ITCI) stock rating was lowered to 'market perform' at JMP Securities on Thursday based on its unsuccessful phase III schizophrenia drug trial.
Shares of Intra-Cellular Therapies plummeted on Thursday as the biopharmaceutical company's phase three trial of its schizophrenia drug was unsuccessful.
IntraCellular Therapies (ITCI) said patients in a schizophrenia drug trial responded better to the placebo medication.